



November 5, 2025

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001.  
**Ref:- Scrip Code:- 500126**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Symbol:- PGHL**

Dear Sir / Madam,

**Sub: Unaudited Financial Results for the quarter ended September 30, 2025**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 12.52 p.m. and ended at 14:21 p.m.), the Unaudited Financial Results for the quarter ended September 30, 2025 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results;
- b. Limited Review Report in respect of the Unaudited Financial Results furnished by Statutory Auditors of the Company.

Kindly take the same on record and oblige.

Thanking you.

For **Procter & Gamble Health Limited**

**Zeal Rupani**  
Company Secretary

**Independent Auditor’s Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)**

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited (“the Company”) for the quarter ended September 30, 2025 and year to date results for the period from April 1, 2025 to September 30, 2025 (“the Statement”), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as “the said Indian Accounting Standard”) and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

# HARIBHAKTI & CO. LLP

Chartered Accountants

5. Attention is drawn to Note 4 to the statement. As mentioned the statement includes the results for the corresponding six months ended September 30, 2024, which is arrived at by adding the published audited figures for the quarter ended June 30, 2024 and the published unaudited figures for the quarter ended September 30, 2024, on which, we had issued a separate limited review report.

Our report is not modified in respect of this matter.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048

SUMANT  
MANGESH  
SAKHARDAN  
DE

Digitally signed by  
SUMANT MANGESH  
SAKHARDANDE  
Date: 2025.11.05  
14:10:41 +05'30'

Sumant Sakhardande

Partner

Membership No. 034828

UDIN: 25034828BMNZMM8061

Place: Mumbai

Date: November 5, 2025

**PROCTER & GAMBLE HEALTH LIMITED**

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2025**

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(4)
		Three months ended 30th September 2025 (Unaudited)	Preceding Three months ended 30th June 2025 (Unaudited)	Corresponding Three months ended 30th September 2024 (Unaudited)	Six months ended 30th September 2025 (Unaudited)	Corresponding Six months ended 30th September 2024 (Unaudited) (refer note 4)	Previous Year (Nine Months) ended 31st March 2025 (Audited) (refer note 3)
1.	Revenue from Operations	32 492	33 874	31 341	66 366	59 729	93 417
2.	Other Income	495	403	328	898	541	1 035
3.	<b>Total income (1+2)</b>	<b>32 987</b>	<b>34 277</b>	<b>31 669</b>	<b>67 264</b>	<b>60 270</b>	<b>94 452</b>
	<b>Expenses</b>						
	a) Cost of materials consumed	7 813	5 954	4 817	13 767	11 559	20 059
	b) Purchases of stock-in-trade (Traded goods)	1 064	2 431	2 016	3 495	3 867	4 716
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	(2 037)	1 014	1 972	(1 023)	1 296	1 475
	d) Employee benefits expenses	5 388	5 601	4 622	10 989	9 485	14 206
	e) Depreciation and amortisation expenses	608	544	577	1 152	1 293	1 669
	f) Finance costs	12	12	15	24	35	43
	g) Other expenses	8 237	9 840	6 510	18 077	17 293	21 122
4.	<b>Total expenses (4)</b>	<b>21 085</b>	<b>25 396</b>	<b>20 529</b>	<b>46 481</b>	<b>44 828</b>	<b>63 290</b>
5.	<b>Profit before exceptional items and tax (3-4)</b>	<b>11 902</b>	<b>8 881</b>	<b>11 140</b>	<b>20 783</b>	<b>15 442</b>	<b>31 162</b>
6.	Less: Exceptional items (refer note 7)	-	-	-	-	2 019	-
7.	<b>Profit before tax (5-6)</b>	<b>11 902</b>	<b>8 881</b>	<b>11 140</b>	<b>20 783</b>	<b>13 423</b>	<b>31 162</b>
8.	<b>Tax expenses</b>						
	a) Current Tax	3 054	2 294	2 795	5 348	4 074	7 763
	b) Deferred Tax Charge / (Credit)	(6)	(31)	112	(37)	(562)	(49)
	c) Adjustment of tax relating to earlier periods	-	-	-	-	-	7
	<b>Total tax expenses</b>	<b>3 048</b>	<b>2 263</b>	<b>2 907</b>	<b>5 311</b>	<b>3 512</b>	<b>7 721</b>
9.	<b>Net Profit for the period / year (7-8)</b>	<b>8 854</b>	<b>6 618</b>	<b>8 233</b>	<b>15 472</b>	<b>9 911</b>	<b>23 441</b>
10.	<b>Other Comprehensive Income</b>						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains / (losses) on defined benefit plans	323	(87)	23	236	(111)	(350)
	ii. Income tax effect on above	(81)	22	(6)	(59)	27	88
	<b>Other Comprehensive Income, net of tax</b>	<b>242</b>	<b>(65)</b>	<b>17</b>	<b>177</b>	<b>(84)</b>	<b>(262)</b>
11.	<b>Total Comprehensive Income for the period / year (9+10)</b>	<b>9 096</b>	<b>6 553</b>	<b>8 250</b>	<b>15 649</b>	<b>9 827</b>	<b>23 179</b>
12.	Paid-up equity share capital (Face Value ₹ 10/- each)	1 660	1 660	1 660	1 660	1 660	1 660
13.	Other equity	-	-	-	-	-	52 036
14.	<b>Earnings per equity share (of ₹ 10/- each)</b> <b>*(not annualised)</b>						
	(a) Basic and Diluted (in ₹) (before exceptional items)	* 53.34	* 39.87	* 49.6	* 93.21	* 71.87	141.22
	(b) Basic and Diluted (in ₹) (after exceptional items)	* 53.34	* 39.87	* 49.6	* 93.21	* 59.71	141.22

## PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investor@pg.com

### Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 5, 2025 and have been subjected to a limited review by the Statutory Auditors of the Company. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and expressed "Unmodified" Conclusion.
2. This Statement has been prepared in accordance with the Companies ("Indian Accounting Standards") Rules, 2015 ("IND AS") prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the previous Financial Year of the Company viz., 2024-25 was for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025.
4. Pursuant to the change in the Financial Year as mentioned in note 3 above, the figures for the corresponding six months ended September 30, 2024 are arrived at by adding the published audited figures for the quarter ended June 30, 2024 and the published unaudited figures for the quarter ended September 30, 2024.
5. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
6. The unaudited financial results are available on the website of the Company ([www.pghealthindia.com](http://www.pghealthindia.com)) and on the websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
7. During the quarter ended June 30, 2024, the Company had discontinued production of injections at its manufacturing plant in Goa effective September 30, 2023, as the Company had started to source injections portfolio of its products from a contract manufacturer. Post evaluation of various alternatives, during the quarter ended June 30, 2024, the Company had entered into an agreement for sale of the assets of its injection plant for a consideration of ₹ 790 Lakhs and impaired the balance amount of ₹ 627 Lakhs. Based on above, the company had re-evaluated the usability of assets in their capital work in progress and thereby impaired other related assets by an amount of ₹ 1 392 Lakhs. The above total amount of ₹ 2 019 Lakhs was disclosed as an exceptional item for the six months ended September 30, 2024.
8. Previous year's/period's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's classification.
9. The Company does not have a subsidiary, an associate or a joint venture as at 30th September, 2025.

For and on behalf of the Board of Directors of

Procter & Gamble Health Limited

**Milind Vasant**  
Thatte

Digitally signed by

Milind Vasant Thatte

Date: 2025.11.05

14:27:15 +05'30'

Milind Thatte

Managing Director

Place : Mumbai

Date : November 05, 2025

**PROCTER & GAMBLE HEALTH LIMITED**
**Statement of Assets and Liabilities**

(₹ in lakhs)

Particulars	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	9,638	10,463
(b) Capital work-in-progress	1,281	1,096
(c) Investment property	411	437
(d) Right -of -use assets	505	640
(e) Intangible assets	53	71
(f) Financial assets		
(i) Loans	982	1,017
(ii) Other financial assets	453	479
(g) Deferred tax assets (net)	3,484	3,506
(h) Other non-current assets	280	291
(i) Non-current tax assets (net)	8,427	8,781
<b>Total non-current assets</b>	<b>25,514</b>	<b>26,781</b>
<b>Current assets</b>		
(a) Inventories	12,733	10,937
(b) Financial assets		
(i) Trade receivables	13,749	14,540
(ii) Cash and cash equivalents	27,930	18,208
(iii) Bank balances other than (ii) above	687	647
(iv) Loans	169	159
(v) Other financial assets	1,594	1,751
(c) Other current assets	6,954	6,287
(d) Assets held for Sale	110	110
<b>Total current assets</b>	<b>63,926</b>	<b>52,639</b>
<b>TOTAL ASSETS</b>	<b>89,440</b>	<b>79,420</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	1,660	1,660
(b) Other equity	60,313	52,036
<b>Total Equity</b>	<b>61,973</b>	<b>53,696</b>
<b>Non-Current Liabilities</b>		
(a) Financial liabilities		
(i) Lease liabilities	335	481
(b) Provisions	4,783	3,612
(c) Other non-current liabilities	100	100
<b>Total non-current liabilities</b>	<b>5,218</b>	<b>4,193</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
(i) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	916	1,208
- Total outstanding dues of creditors other than micro enterprises and small enterprises	16,618	15,952
(ii) Lease Liabilities	285	281
(iii) Other financial liabilities	1,787	1,666
(b) Provisions	889	697
(c) Current tax liabilities (net)	967	345
(d) Other current liabilities	787	1,382
<b>Total current liabilities</b>	<b>22,249</b>	<b>21,531</b>
<b>Total liabilities</b>	<b>27,467</b>	<b>25,724</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>89,440</b>	<b>79,420</b>

**Procter & Gamble Health Limited**
**Statement of Cash Flows for the six months ended September 30, 2025**

(₹ in lakhs)

Particulars	Six Months ended September 30, 2025 (Un-Audited)	Financial Year (nine months) ended March 31, 2025 (refer note 3) (Audited)
<b>A. Cash Flows from Operating Activities</b>		
<b>Profit before tax</b>	<b>20 783</b>	<b>31 162</b>
<i>Adjustments for:</i>		
Net unrealised foreign exchange (Gain)/Loss	17	( 35)
Allowance for doubtful receivables/ other assets	(391)	59
Provision for Inventory (net of reversals)	297	211
Provision/ write off of GST and other taxes	835	158
Depreciation and amortization expense	1,152	1 669
Rental income	(220)	( 310)
Provision for employee benefits	68	36
Loss on sale of property, plant and equipment	172	13
Share-based payment to employees	98	80
Finance costs	24	43
Interest income	(530)	( 704)
<b>Operating profit before working capital changes</b>	<b>22 305</b>	<b>32 382</b>
Working capital adjustments:		
(Increase)/Decrease in inventories	(2 093)	( 237)
Decrease/(Increase) in trade receivables	1 165	(6 031)
(Increase)/Decrease in financial and other Assets	(1 267)	( 724)
Increase/(Decrease) in trade payables	622	693
Increase/(Decrease) in other liabilities and provisions	863	(1 082)
<b>Cash generated from operations</b>	<b>21 595</b>	<b>25 001</b>
Income taxes paid (net)	(4 372)	(8 132)
<b>Net cash flows generated from operating activities (A)</b>	<b>17 223</b>	<b>16 869</b>
<b>B. Cash Flows from Investing Activities</b>		
Purchase and construction of property, plant & equipment, capital work-in-progress	( 599)	( 856)
Proceeds from disposal of property plant & equipment and assets held for sale	9	790
Rental income	220	310
Interest received	511	715
<b>Net cash flows generated from/(used in) investing activities (B)</b>	<b>141</b>	<b>959</b>
<b>C. Cash flow from financing activities</b>		
Dividend paid	(7 470)	(23 240)
Payment of lease liability	( 164)	( 234)
<b>Net cash flows (used in) financing activities (C)</b>	<b>(7 634)</b>	<b>(23 474)</b>
<b>Net (decrease) in cash and cash equivalents (A+B+C)</b>	<b>9 729</b>	<b>(5 646)</b>
Cash and cash equivalents at the beginning of the year	<b>18 227</b>	<b>23 873</b>
<b>Cash and cash equivalents at the end of the period/year</b>	<b>27 956</b>	<b>18 227</b>
<b>Components of Cash and Cash equivalents at the end of the period/ year:</b>		
In Current accounts	<b>6 956</b>	<b>9 227</b>
In Term deposits (having original maturity of less than three months)	<b>21 000</b>	<b>9 000</b>
	<b>27 956</b>	<b>18 227</b>